Genomic Instability and Cancer

Home > Teams > Genomic Instability and Cancer

Genomic Instability and Cancer

In the EU-28, cancer accounts for 25.8% of the total number of deaths, acquiring the second position behind cardiovascular diseases. In 2012, among the EU member states, the highest standardized death rates for cancer were recorded in Hungary and Croatia, both with rates over 330 per 100 000 inhabitants (EuroStat data). During the past decade(s), significant developments have been made to lower the burdens related to cancer and its complications.

Group Name

Group Leader

Details

HCEMM-USZ Magnetotherapeutics Research Group

Antal Berényi MD, PhD

HCEMM-SU Molecular Oncohematology Research Group

Csaba Bödör PhD

HCEMM-BRC Mutagenesis and Carcinogenesis Research Group

Lajos Haracska PhD

Genome Integrity and DNA Repair Core Group

Tibor Pankotai Ph.D., habil

HCEMM-BRC Systems Immunology Research Group

Máté Manczinger Ph.D.

Cancer genomics and epigenetics

Lőrinc Sándor Pongor, PhD

HCEMM-SE Translational Dermatology Research Group

Lajos Vince Kemény MD, PhD

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 739593. HCEMM supported by EU Programme: H2020-EU.4.a. – Teaming of excellent research institutions and low performing RDI regions. Project starting date was 1 April 2017.

Awards

Consortium

About HCEMM

Hungarian Centre of Excellence for Molecular Medicine is a strong catalyst of reformative changes in biomedical science and in institutional research management.

National VAT number: 26307383-2-06
EU VAT number: HU26307383

Internal Policies

Contact Info

Copyright © 2023 Hungarian Centre of Excellence for Molecular Medicine, all rights reserved. Hungarian Centre of Excellence for Molecular Medicine® and HCEMM® are registered trademarks of the the HCEMM Nonprofit Ltd.